Precision Medicine Advances Through Genetic Testing and AI Integration

Precision medicine is reshaping healthcare delivery by using patient-specific data, including genetics, to guide treatment decisions and identify risks earlier. Advances in technology, including wearable devices and artificial intelligence, are expanding this approach, improving personalization of care while helping reduce health complications and cost over time for patients. Research demonstrates that direct-to-consumer genetic testing can identify previously unknown health risks and spur real-world medical action when results are shared with healthcare professionals.

Precision medicine uses genetics and patient data to guide care, helping identify risk earlier and deliver more targeted treatment across areas like cancer care and medication management. The approach has transformed healthcare from organ-based treatment algorithms to biologically stratified care, with genomic sequencing, pharmacogenomics, biomarker-driven oncology, and advanced gene and cell therapies now allowing physicians to tailor interventions to each patient's molecular profile.

A recent study of over 1,000 consenting participants who received results for medically actionable conditions found that 82% of individuals with a medically actionable genetic variant identified through direct-to-consumer testing were unaware of their genetic risk beforehand, even though most (68%) reported a personal or family history of a related health condition. When people took their genetic results to a healthcare professional, it often led to important, personalized health actions, with almost 1,500 medical recommendations made by healthcare professionals based on individuals' genetic results, including follow-up blood testing, cancer screenings, starting medications and preventive surgery.

The overall adherence to medical recommendations was high at 88%, with people following their doctor's medical advice and taking action based on their genetic results. However, less than half of research participants (46%) reported sharing their results with a healthcare professional, though for those who did share, 86% received at least one medical recommendation. The study also identified a potential disparity, finding that individuals with variants in the TTR gene, which were more common in non-White individuals, had the lowest rates of prior genetic testing and were less likely to receive medical recommendations after sharing their results with a healthcare professional.

Artificial intelligence is starting to change how care is delivered, with leaders highlighting its ability to expand access and strengthen healthcare systems. In clinical settings, tools that capture and organize notes are cutting time spent on documentation, while AI is being used to better connect patients to care, particularly in rural areas where access has long been limited. This shift toward "healthcare without walls" represents a fundamental step change in the way medicine is practiced.

Despite these advances, current reimbursement systems remain rooted in fee-for-service, a model designed to reward repeatable procedures and standardized encounters. This creates a growing gap between how value is generated in modern medicine and how it is reimbursed. Under fee-for-service, providers earn more revenue from multiple infusions than from a single, biologically precise intervention, meaning the unit of payment often does not reflect the true unit of clinical value.

Billing infrastructure still depends on CPT and ICD codes, which were designed around procedures and diagnoses rather than genomic subtypes. Patients coded identically for the same disease may have completely different molecular drivers, yet reimbursement treats them the same. Coverage policies differ widely across commercial insurers, Medicare contractors, and Medicaid programs, with most payers requiring preauthorization before molecular testing, documentation of guideline adherence, mutation confirmation before drug approval, and evidence of prior therapy failure.

Achieving sustainable deployment of precision medicine at scale requires structural modernization of reimbursement, operational excellence in billing, and coordinated collaboration among payers, providers, and life sciences stakeholders. Personalized reimbursement models link payment to clinical outcomes or episode-level value, classify patients using biomarker-informed frameworks, and share outcome risk between payer and manufacturer, sometimes including the provider.